Legal basis: art. 17. 1 MAR. & Lt; br / & gt; Krka, dd, Novo mesto (hereinafter referred to as Krka). Krka Sverige AB, Sweden, (Hereinafter referred to as Krka Sverige) received the decision of the Eastern High Court in Copenhagen, Denmark, in the litigation for alleged infringement of the EP 1 020 461 patent in Denmark commenced by AstraZeneca, Sweden, and AstraZeneca, Denmark, (hereinafter referred to as AstraZeneca) against Krka Sverige. & Lt; br / & gt; The EP 1 020 461 patent protects the active substance esomeprazole with high optical purity, while active ingredient esomeprazole is not patent protected as a new medicine. & Lt; br / & gt; In February 2016, the Krka Sverige had infringed the patent and awarded damages to AstraZeneca. & Lt; br / & gt; Krka Sverige appealed to this first instance decision. After the trial of the Eastern High Court in Copenhagen. The Court found that Krka Sverige had a claim for damages. & Lt; br / & gt; The decision is final. AstraZeneca can file an application for leave to appeal at the Danish Supreme Court. & Lt; br / & gt; Krka published on November 15, 2010, April 11, 2013 and February 25, 2016. & lt; br / & gt;
Source: company website, investor relations, current and periodic reports.